(FM) Hematología
Departamento académico
Princess Margaret Cancer Centre
Toronto, CanadáPrincess Margaret Cancer Centre-ko ikertzaileekin lankidetzan egindako argitalpenak (10)
2022
-
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33
-
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 7, pp. 483-494
-
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
The Lancet Oncology, Vol. 23, Núm. 8, pp. 1055-1065
-
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
Cancers, Vol. 14, Núm. 3
2021
-
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Future Oncology, Vol. 17, Núm. 16, pp. 1987-2003
-
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Blood Cancer Journal, Vol. 11, Núm. 6
-
Minimal residual disease in Myeloma: Application for clinical care and new drug registration
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212
-
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Journal of Hematology and Oncology
2020
-
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
The Lancet Oncology, Vol. 21, Núm. 2, pp. 207-221